Brief Report - (2025) Volume 9, Issue 4
Received: 01-Jul-2025, Manuscript No. jma-26-184599;
Editor assigned: 03-Jul-2025, Pre QC No. P-184599;
Reviewed: 17-Jul-2025, QC No. Q-184599;
Revised: 22-Jul-2025, Manuscript No. R-184599;
Published:
29-Jul-2025
, DOI: 10.37421/2684-4265.2025.09.389
Citation: McAllister, Peter J.. ”Sarcopenia: Muscle Loss, Aging, and Cellular Dysfunction.” J Morphol Anat 09 (2025):389.
Copyright: © 2025 McAllister J. Peter This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Sarcopenia, a pervasive condition characterized by the age-related decline in skeletal muscle mass and strength, arises from a complex tapestry of cellular and molecular alterations. This multifaceted process significantly impacts an individual's functional capacity and quality of life, necessitating a thorough understanding of its underlying mechanisms [1].
At the cellular level, aging skeletal muscle is marked by a reduced oxidative capacity, primarily attributed to a decline in mitochondrial function. This manifests as diminished mitochondrial volume, altered internal structure (cristae), and impaired electron transport chain activity, ultimately compromising ATP production and increasing oxidative stress [2].
Integral to muscle regeneration are satellite cells, the resident muscle stem cells. With advancing age, these critical cells undergo senescence, leading to a reduction in their numbers and a significant impairment in their ability to proliferate and differentiate, thereby hindering muscle repair and adaptation responses [3].
The extracellular matrix (ECM) within skeletal muscle also undergoes substantial remodeling during aging. An accumulation of collagen and other matrix proteins leads to increased muscle stiffness and reduced contractility, a process that can interfere with cellular signaling and contribute to a pro-inflammatory milieu [4].
Furthermore, aging muscle fibers often exhibit a preferential loss of type II (fast-twitch) fibers. This shift in fiber type composition towards a greater proportion of type I (slow-twitch) fibers directly impacts power output and the capacity for rapid force generation [5].
The infiltration of intramuscular adipose tissue (IMAT) and connective tissue also escalates with age. This 'degenerative' component replaces functional muscle tissue, diminishing muscle density and impairing the efficient transmission of force, while also being linked to metabolic dysfunction and inflammation [6].
Calcium handling, a fundamental process for muscle contraction and relaxation, becomes dysregulated in aging skeletal muscle. Impaired calcium homeostasis, stemming from alterations in sarcoplasmic reticulum function, can reduce excitation-contraction coupling efficiency, contributing to fatigue and weakness [7].
Alterations at the neuromuscular junction (NMJ) are another defining feature of aging muscle. A loss of NMJ integrity, coupled with reduced acetylcholine receptor density and impaired neurotransmission, can lead to muscle denervation and a decline in motor unit function [8].
Chronic low-grade inflammation, often referred to as 'inflammaging', significantly contributes to sarcopenia. Elevated levels of pro-inflammatory cytokines can accelerate muscle protein breakdown and inhibit synthesis, creating a catabolic state that exacerbates muscle loss [9].
Finally, the delicate balance between muscle protein synthesis and degradation is disrupted in aging. Reduced rates of synthesis, often due to anabolic resistance to stimuli like exercise and nutrition, combined with potentially increased degradation, result in a net loss of muscle protein over time [10].
Sarcopenia, a prevalent age-associated decline in skeletal muscle mass and strength, is underpinned by a complex interplay of cellular and molecular changes. Morphologically, muscle fibers undergo atrophy and a preferential loss of fast-twitch fibers, alongside an increase in intramuscular fat and connective tissue, collectively diminishing muscle quality [1].
A key molecular alteration in aging muscle is mitochondrial dysfunction, characterized by reduced oxidative capacity. This involves decreased mitochondrial volume, altered cristae morphology, and impaired electron transport chain function, leading to diminished ATP production and elevated reactive oxygen species [2].
Satellite cells, crucial for muscle regeneration, exhibit a decline in number and function with age. This senescence involves altered gene expression and reduced proliferative and differentiative potential, compromising the muscle's ability to repair and adapt to stress [3].
The extracellular matrix (ECM) undergoes significant remodeling in aging skeletal muscle, with an accumulation of collagen and other proteins. This fibrotic process increases muscle stiffness, impairs contractility, and can disrupt cellular signaling, contributing to functional decline [4].
A distinct characteristic of aging muscle is the preferential loss of type II (fast-twitch) fibers, leading to a shift towards a higher proportion of type I (slow-twitch) fibers. This alteration directly impacts the muscle's capacity for power output and rapid force generation [5].
Concurrently, there is an increase in intramuscular adipose tissue (IMAT) and connective tissue infiltration. This replacement of functional muscle tissue with adipocytes and fibrotic elements reduces muscle density and impairs force transmission, further contributing to sarcopenic changes [6].
Calcium handling mechanisms are disrupted in aging skeletal muscle, affecting sarcoplasmic reticulum function. This dysregulation in calcium homeostasis impairs excitation-contraction coupling efficiency, which can manifest as reduced muscle force and increased fatigue [7].
Alterations at the neuromuscular junction (NMJ) are a hallmark of aging muscle, involving a loss of integrity, reduced acetylcholine receptor density, and impaired neurotransmission. These changes contribute to muscle denervation and a decline in the functional capacity of motor units [8].
Chronic low-grade inflammation, or 'inflammaging', plays a significant role in sarcopenia. Pro-inflammatory cytokines can directly promote muscle protein breakdown and inhibit synthesis, establishing a catabolic environment that accelerates muscle wasting [9].
Finally, aging skeletal muscle often experiences an imbalance in protein metabolism, with reduced rates of protein synthesis and/or increased degradation. This anabolic resistance to stimuli like exercise and nutrition leads to a net loss of muscle protein, a critical factor in sarcopenia progression [10].
Sarcopenia is an age-related condition involving the decline of skeletal muscle mass and strength. Key factors contributing to this decline include muscle fiber atrophy, particularly of fast-twitch fibers, and increased intramuscular fat and connective tissue. Mitochondrial dysfunction, impaired calcium handling, and satellite cell senescence further compromise muscle function and regeneration. Changes in the extracellular matrix, neuromuscular junctions, and chronic inflammation also play significant roles. An imbalance in muscle protein synthesis and degradation pathways, characterized by anabolic resistance, ultimately leads to a net loss of muscle protein and contributes to the progression of sarcopenia.
None
None
Journal of Morphology and Anatomy received 63 citations as per Google Scholar report
